A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer 1

@inproceedings{Dowlati2002API,
  title={A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer 1},
  author={Afshin Dowlati and Kelly A Robertson and Matthew A. Cooney and William P. Petros and Michael Stratford and John A. Jesberger and Niusha Rafie and Beth A. Overmoyer and Vinit Makkar and Bruce Sheldon Stambler and Anne W Taylor and John K Waas and Jonathan S. Lewin and Keith R McCrae and Scot C. Remick},
  year={2002}
}
Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to enter the clinic. We performed a Phase I trial to determine the maximum-tolerated dose, safety, and pharmacokinetic profile of CA4P on a single-dose i.v. schedule. We also obtained preliminary data on its effect on tumor blood… CONTINUE READING